Hansen Medical Announces Initiation of Sell-Side Coverage by Cowen and Company
27 6월 2013 - 5:01AM
Marketwired
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in
intravascular robotics, today announced that Cowen and Company has
initiated sell-side coverage of Hansen Medical. The report was
authored by Joshua Jennings, M.D., Director and Senior Research
Analyst for medical devices.
About Analyst Coverage of Hansen Medical
Hansen Medical is followed by several analysts, including Cowen and
Company. Any opinions, estimates, forecasts or statements regarding
Hansen Medical's performance made by Cowen and Company or other
analysts are theirs alone and do not represent opinions, estimates,
forecasts or statements of Hansen Medical or its management. This
press release does not imply Hansen Medical's endorsement of or
concurrence with the information, conclusions or recommendations of
Cowen and Company or any other analyst.
About Hansen Medical, Inc. Hansen Medical,
Inc., based in Mountain View, California, is the global leader in
intravascular robotics, developing products and technology designed
to enable the accurate positioning, manipulation and control of
catheters and catheter-based technologies. The Company's Magellan™
Robotic System, Magellan Robotic Catheter and related accessories,
which are intended to facilitate navigation to anatomical targets
in the peripheral vasculature and subsequently provide a conduit
for manual placement of therapeutic devices, have undergone both CE
marking and 510(k) clearance and are commercially available in the
European Union, and the U.S. In the European Union, the Company's
Sensei® X Robotic Catheter System and Artisan Control Catheter are
cleared for use during electrophysiology (EP) procedures, such as
guiding catheters in the treatment of atrial fibrillation (AF), and
the Lynx® Robotic Ablation Catheter is cleared for the treatment of
AF. This robotic catheter system is compatible with fluoroscopy,
ultrasound, 3D surface map and patient electrocardiogram data. In
the U.S. the Company's Sensei X Robotic Catheter System and Artisan
Control Catheter were cleared by the U.S. Food and Drug
Administration for manipulation and control of certain mapping
catheters in EP procedures. In the United States, the Sensei System
is not approved for use in guiding ablation procedures; this use
remains experimental. The U.S. product labeling therefore provides
that the safety and effectiveness of the Sensei X System and
Artisan Control Catheter for use with cardiac ablation catheters in
the treatment of cardiac arrhythmias, including AF, have not been
established. Additional information can be found at
www.hansenmedical.com.
About Cowen and Company Cowen Group, Inc.
is a diversified financial services firm and, together with its
consolidated subsidiaries, provides alternative investment
management, investment banking, research, and sales and trading
services through its two business segments: Ramius LLC and its
affiliates makes up the Company's alternative investment management
segment, while Cowen and Company, LLC is its broker-dealer segment.
Its alternative investment management products, solutions and
services include hedge funds, replication products, managed futures
funds, fund of funds, real estate, health care royalty funds and
cash management services. Cowen and Company offers industry focused
investment banking for growth-oriented companies, domain
knowledge-driven research and a sales and trading platform for
institutional investors. Founded in 1918, the firm is headquartered
in New York and has offices located in major financial centers
around the world.
Investor Contacts: Peter J. Mariani Chief Financial
Officer Hansen Medical, Inc. 650.404.5800 FTI Consulting,
Inc. Brian Ritchie 212.850.5683 Email Contact John Capodanno
212.850.5705 Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024